Key Highlights

  • Collaboration Revenue was USD 1.0 million, with none a year earlier.
  • Loss per share was USD 0.28 against an estimate of a USD 0.38 loss.
  • Net loss was USD 1.75 million, against Net Income of USD 26.8 thousand.
  • Cash was USD 5.57 million and short-term investments were USD 10.72 million.

Kiora Pharmaceuticals (NASDAQ:KPRX) reported third quarter 2026 collaboration revenue of USD 1.0 million, with no revenue in the third quarter of 2025. The loss per share was USD 0.28, against an estimate of a USD 0.38 loss, compared with Earnings of USD 0.01 per share a year earlier.

Net loss was USD 1.75 million, compared with net income of USD 26.8 thousand. The operating loss was USD 1.69 million, compared with USD 794.4 thousand.

Operating Expenses

Research and development expenses were USD 1.95 million, compared with USD 2.73 million. General and administrative expenses were USD 1.58 million, compared with USD 1.44 million. Total operating expenses were USD 2.69 million, compared with USD 794.4 thousand.

Nine-Month Results

For the nine months ended September 30, 2026, net loss was USD 6.25 million, compared with USD 4.32 million, and the loss per share was USD 1.12, compared with USD 1.04. The operating loss for the nine months was USD 6.41 million, compared with USD 5.52 million.

Research and development expenses for the nine months were USD 6.15 million, compared with USD 7.85 million, and general and administrative expenses were USD 4.58 million, compared with USD 4.29 million. Total operating expenses were USD 7.41 million, compared with USD 5.52 million.

Liquidity and Going Concern

Cash and cash equivalents were USD 5.57 million, compared with USD 8.70 million at the prior Balance Sheet date, and short-term investments were USD 10.72 million, compared with USD 8.39 million.

The filing states that the factors it describes have caused management to determine that there is substantial doubt about the company's ability to continue as a going concern. It states that the company plans to seek to fund operations through a combination of public or private sales of equity, debt financings, license and development agreements, non-dilutive grants and other sources, which may include collaborations with third parties.

The filing states that the company has entered into license agreements with Thea Open Innovation and Chong Kun Dang Pharmaceutical Corporation, and an option agreement with Senju Pharmaceutical Co., Ltd. Subsequent to the reporting period, in October 2026, the company entered into a license agreement with Senju.

The filing explains that milestone payments not within the company's or a collaboration partner's control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received, and that amounts received before the revenue recognition criteria are satisfied are recorded as deferred revenue.

The filing reports collaboration revenue of USD 1.0 million for both the quarter and the nine months, with no revenue in the prior-year periods, and states that the company records amounts received before the revenue recognition criteria are met as deferred revenue.

Kiora Pharmaceuticals Q3 2026 Earnings: Key Takeaways

Kiora Pharmaceuticals reported third quarter 2026 collaboration revenue of USD 1.0 million and a loss per share of USD 0.28. The filing includes a Going Concern disclosure and describes an October 2026 license agreement with Senju.